What does the future hold for oral chemotherapeutic agents? Will they one day replace infusion therapies? Could they even transform cancer into a chronic, manageable disease treatable at home? Host Dr. Charles Turck speaks with Dr. Susan Goodin, Director of the Division of Pharmaceutical Sciences at The Cancer Institute of New Jersey, about the remarkable progress in research and development for oral chemotherapeutics.
The Future of Oral Chemotherapeutic Agents
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
What does the future hold for oral chemotherapeutic agents? Will they one day replace infusion therapies? Could they even transform cancer into a chronic, manageable disease treatable at home? Host Dr. Charles Turck speaks with Dr. Susan Goodin, Director of the Division of Pharmaceutical Sciences at The Cancer Institute of New Jersey, about the remarkable progress in research and development for oral chemotherapeutics.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
Clinician's Roundtable
AI and Hair Loss: Measuring Progress with Data-Driven Insights
<p>AI and Hair Loss: Measuring Progress with Data-Driven Insights</p>
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
<p>Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF</p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Cardiology
FINE-HEART Pooled Analysis
<p><span data-teams="true">FINE-HEART Pooled Analysis</span></p>
Cardiology
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
<p><span data-teams="true">Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial</span> </p>
Cardiology
NYHA FC and Finerenone Response: Clinical Trial Insights
<p><span data-contrast="auto" xml:lang="EN-US">NYHA FC and Finerenone Response: Clinical Trial Insights</span><span data-ccp-props='{"134245417":false,"335559739":0}'> </span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?